GBT1118

**GBT1118** is a potent, orally active small molecule that functions as an allosteric modifier of hemoglobin (Hb) oxygen affinity. It binds reversibly (via an imine intermediate) to the NH₂-terminal valine of the Hb α-chain, increasing the affinity of Hb for oxygen. GBT1118 is a structural analog of voxelotor (also known as Oxbryta) and has been investigated primarily in the context of sickle cell disease (SCD). By increasing hemoglobin oxygen affinity, GBT1118 inhibits HbS polymerization, reduces red blood cell sickling, improves red blood cell deformability, and increases hemoglobin and hematocrit. Preclinical studies demonstrate that GBT1118 preserves red blood cell health by reducing hypoxia-induced membrane damage and confers protective effects in models of hypoxia and SCD, including improvements in anemia, survival during hypoxic stress, tissue oxygenation, and attenuation of bone disease[1][2][3][4][5][6][7].

Other names

voxelotor analogOxbryta analog